Background & Aims The comparative efficacy and safety of infliximab and azathioprine
therapy alone or in combination for ulcerative colitis (UC) have not been evaluated …

Aim To perform a systematic review and metaanalysis on the efficacy and tolerance of
infliximab in ulcerative colitis. Methods Selection of studies: evaluating efficacy of infliximab …

Background: Infliximab is a chimeric immunoglobulin G1κ monoclonal antibody that binds
with high affinity and specificity to the soluble form of tumor necrosis factor (TNF)-α …

Abstract Background/Aims Infliximab is currently used for the treatment of moderateto
severe ulcerative colitis (UC) with an inadequate response to conventional agents. The …

OBJECTIVES: Tumor necrosis factor-α (TNF-α) is an important cytokine involved in the
pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-α, infliximab …

OBJECTIVES: The objective of this study was to evaluate short-and long-term outcomes of
infliximab in ulcerative colitis (UC), including infliximab optimization, colectomy, and …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis
factor α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods …

Background The aim was to evaluate long-term efficacy, quality of life, and safety in
ulcerative colitis patients who received infliximab during the ACT-1 and-2 extension studies …

Aliment Pharmacol Ther 2010; 32: 522–528 Summary Background Randomized, controlled
trials have demonstrated that antiTNF agents are efficacious in inducing remission in cases …

Background. Conventional treatment options for patients with severe steroid-refractory
ulcerative colitis include intravenous cyclosporine, which is frequently burdened by toxicity …